FDA Okays Belzutifan for Pheochromocytoma or Paraganglioma
The US Food and Drug Administration (FDA) has approved belzutifan (Welireg, Merck) for adult and pediatric patients aged 12 years or older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). It is the first US approval of “an oral therapy for PPGL,” the FDA said in a press release…
The US Food and Drug Administration (FDA) has approved belzutifan (Welireg, Merck) for adult and pediatric patients aged 12 years or older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). It is the first US approval of “an oral therapy for PPGL,” the FDA said in a press release…
Read More
About Author
